Skip to content
Kenya BioVax Institute
-
Kenya to triple science funding by 2036 as the KEMRI’s 16th KASH Conference begins in Nairobi
The conference has attracted significant participation, with 405 scientific abstracts submitted and 22 symposiums scheduled throughout the week.
-
Kenya accelerates local vaccine production with 2027 target as CS Duale visits Kenya BioVax Institute
The government has fully funded the first phase of the vaccine manufacturing facility, which has already reached completion.
-
Kenya BioVax Institute welcomes Dr. Wesley Ronoh as substantive CEO, succeeding Dr. Cecilia Wanjala
The handover ceremony took place at the Kenya BioVax headquarters and was presided over by Dr. Charles Githinji, the Chairman of the Board of Directors.